Nasal Allergy News and Research

RSS

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

UCB and sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved XYZAL(R) (levocetirizine dihydrochloride) for children age six months and older for the relief of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) and for children age two years and older for symptoms of seasonal allergic rhinitis (outdoor allergies).

25 Aug 2009

Schering-Plough announces agreement with Orchid Chemicals & Pharmaceuticals on generic forms of CLARINEX

Schering-Plough Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine).

12 Aug 2009

Alcon's PATANASE nasal spray approved by FDA for treatment of nasal allergy symptoms

Alcon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved PATANASE(R) (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.

16 Apr 2008

FDA approves only once-daily inhaled corticosteroid for children

Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved ASMANEX TWISTHALER 110 mcg (mometasone furoate inhalation powder) for the maintenance treatment of asthma as a preventive therapy in patients 4 to 11 years of age.

4 Feb 2008

New once a day asthma treatment approved by FDA

More than 5,000 people die from asthma each year in the United States. Although asthma deaths are infrequent, they have increased significantly during the last two decades.

4 Apr 2005

Olopatadine nasal spray shown to minimise hay fever

Alcon announced today results from a Phase III clinical trial demonstrating that olopatadine nasal spray, a nasal formulation of its market leading ophthalmic anti-allergy product, Patanol(R) ophthalmic solution, reduced seasonal allergic rhinitis (SAR) symptoms compared to placebo.

22 Mar 2004